A Phase I Trial and Pharmacokinetic Study of a 24-hour Infusion of Trabectedin (Yondelis® ET-743) in Children and Adolescents with Relapsed or Refractory Solid Tumors

摘要

BackgroundThe objectives of this phase I study were to determine the maximum tolerated dose (MTD), toxicity profile and pharmacokinetics of a 24-hour continuous intravenous infusion of trabectedin administered to children and adolescents with refractory or relapsed solid tumors.